Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed

Journal of Clinical Oncology

Volumn 33, Issue 34, 2015, Pages 4039-4047

  Hurwitz, Herbert I ^a   Uppal, Nikhil ^b   Wagner, Stephanie A ^c   Bendell, Johanna C ^e   Beck, J Thaddeus ^f   Wade, Seaborn M ^g   Nemunaitis, John J ^h   Stella, Philip J ⁱ   Pipas, J Marc ^j   Wainberg, Zev A ^k   Manges, Robert ^d   Garrett, William M ^l   Hunter, Deborah S ^l   Clark, Jason ^l   Leopold, Lance ^l   Sandor, Victor ^l   Levy, Richard S ^l  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Investigative Clinical Research of Indiana   (United States)

^e SARAH CANNON RESEARCH INSTITUTE   (United States)

^f Highlands Oncology Group   (United States)

^g Virginia Cancer Institute   (United States)

^h Mary Crowley Medical Research Center   (United States)

ⁱ Saint Joseph Mercy Health System   (United States)

^j NORRIS COTTON CANCER CENTER   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l Experimental Station   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CAPECITABINE; GEMCITABINE; RUXOLITINIB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; PYRAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; ASCITES; ASTHENIA; BACKACHE; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; FLATULENCE; GLASGOW OUTCOME SCALE; HAND FOOT SYNDROME; HUMAN; HYPONATREMIA; HYPOTENSION; INFLAMMATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTATIC PANCREATIC CANCER; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS METASTASIS; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VERY ELDERLY; VOMITING; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; CANCER STAGING; CLINICAL TRIAL; COHORT ANALYSIS; FOLLOW UP; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPECITABINE; COHORT STUDIES; DEOXYCYTIDINE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; PYRAZOLES; SURVIVAL RATE;

EID: 84951828799     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.4578     Document Type: Article

References (69)

1. World Health Organization International Agency for Research on Cancer: GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact-sheets-population. aspx
2. National Cancer Institute: Surveillance, Epidemiology, and End Results (SEER) stat fact sheets: Pancreas cancer. http://seer.cancer.gov/statfacts/html/pancreas.html
3. Bilimoria KY, Bentrem DJ, Ko CY, et al: National failure to operate on early stage pancreatic cancer. Ann Surg 246:173-180, 2007
4. Von Hoff DD, Ervin T, Arena FP, et al: Increased survival in pancreatic cancer with nabpaclitaxel plus gemcitabine. N Engl J Med 369: 1691-1703, 2013
5. Seufferlein T, Bachet JB, Van Cutsem E, et al: Pancreatic adenocarcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23:vii33-vii40, 2012 (suppl 7)
6. National Comprehensive Cancer Network (NCCN): NCCN clinical practice guidelines in oncology: Pancreatic adenocarcinoma v.1.2014. http://www.nccn.org/professionals/physician-gls/pdf/pancreatic.pdf
7. Pelzer U, Schwaner I, Stieler J, et al: Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group. Eur J Cancer 47:1676-1681, 2011
8. Rahma OE, Duffy A, Liewehr DJ, et al: Second-line treatment in advanced pancreatic cancer: A comprehensive analysis of published clinical trials. Ann Oncol 24:1972-1979, 2013
9. Elinav E, Nowarski R, Thaiss CA, et al: Inflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 13:759-771, 2013
10. Qu X, Zhuang G, Yu L, et al: Induction of Bv8 expression by granulocyte colony-stimulating factor in CD11b-Gr1- cells: Key role of Stat3 signaling. J Biol Chem 287:19574-19584, 2012
11. Diakos CI, Charles KA, McMillan DC, et al: Cancer-related inflammation and treatment effectiveness. Lancet Oncol 15:e493-e503, 2014
12. Guthrie GJ, Roxburgh CS, Horgan PG, et al: Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses and outcome in patients with colorectal cancer? Cancer Treat Rev 39:89-96, 2013
13. Fearon K, Arends J, Baracos V: Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol 10:90-99, 2013
14. Fearon KC, Barber MD, Falconer JS, et al: Pancreatic cancer as a model: Inflammatory mediators, acute-phase response, and cancer cachexia. World J Surg 23:584-588, 1999
15. Laird BJ, McMillan DC, Fayers P, et al: The systemic inflammatory response and its relationship to pain and other symptoms in advanced cancer. Oncologist 18:1050-1055, 2013
16. Fearon KC, Voss AC, Hustead DS, et al: Definition of cancer cachexia: Effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 83:1345-1350, 2006
17. Nixon AB, Pang H, Starr MD, et al: Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB80303 (Alliance). Clin Cancer Res 19:6957-6966, 2013
18. Nakachi K, Furuse J, Ishii H, et al: Prognostic factors in patients with gemcitabine-refractory pancreatic cancer. Jpn J Clin Oncol 37:114-120, 2007
19. McMillan DC: The systemic inflammationbased Glasgow prognostic score: A decade of experience in patients with cancer. Cancer Treat Rev 39:534-540, 2013
20. Allin KH, Nordestgaard BG: Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci 48:155-170, 2011
21. Han Y, Mao F, Wu Y, et al: Prognostic role of C-reactive protein in breast cancer: A systematic review and meta-Analysis. Int J Biol Markers 26:209-215, 2011
22. Ridker PM, Kastelein JJ, Genest J, et al: C-reactive protein and cholesterol are equally strong predictors of cardiovascular risk and both are important for quality clinical care. Eur Heart J 34:1258-1261, 2013
23. Food and Drug Administration: Guidance for Industry and FDA Staff: Review criteria for assessment of C-reactive protein (CRP), high sensitivity C-reactive protein (hsCRP) and cardiac C-reactive protein (cCRP) assays. Silver Spring, MD, US Department of Health and Human Services, 2005
24. McMillan DC, Elahi MM, Sattar N, et al: Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 41:64-69, 2001
25. Lesina M, Kurkowski MU, Ludes K, et al: Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19:456-469, 2011
26. Li H, Huang C, Huang K, et al: STAT3 knockdown reduces pancreatic cancer cell invasiveness and matrix metalloproteinase-7 expression in nude mice. PLoS One 6:e25941, 2011
27. Scholz A, Heinze S, Detjen KM, et al: Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology 125: 891-905, 2003
28. Wei D, Le X, Zheng L, et al: Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22:319-329, 2003
29. Phesse TJ, Buchert M, Stuart E, et al: Partial inhibition of gp130-Jak-Stat3 signaling prevents Wnt-beta-catenin-mediated intestinal tumor growth and regeneration. Sci Signal 7:ra92, 2014
30. Sansone P, Bromberg J: Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 30:1005-1014, 2012
31. Silva CM: Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 23:8017-8023, 2004
32. Sen M, Joyce S, Panahandeh M, et al: Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res 18:4986-4996, 2012
33. Alvarez JV, Greulich H, Sellers WR, et al: Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-Associated mutations of the epidermal growth factor receptor. Cancer Res 66:3162-3168, 2006
34. Xu Q, Briggs J, Park S, et al: Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24:5552-5560, 2005
35. Jenkins BJ, Grail D, Nheu T, et al: Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling. Nat Med 11:845-852, 2005
36. Zhao S, Venkatasubbarao K, Lazor JW, et al: Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells. Cancer Res 68:4221-4228, 2008
37. Yao Z, Fenoglio S, Gao DC, et al: TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci USA 107:15535-15540, 2010
38. O'Shea JJ, Holland SM, Staudt LM: JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 368:161-170, 2013
39. Quintas-Cardama A, Kantarjian H, Cortes J, et al: Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 10:127-140, 2011
40. Fouad TM, Kogawa T, Reuben JM, et al: The role of inflammation in inflammatory breast cancer. Adv Exp Med Biol 816:53-73, 2014
41. Nguyen DP, Li J, Tewari AK: Inflammation and prostate cancer: The role of interleukin 6 (IL-6). BJU Int 113:986-992, 2014
42. Yu H, Pardoll D, Jove R: STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer 9:798-809, 2009
43. Rauch I, Muller M, Decker T: The regulation of inflammation by interferons and their STATs. JAKSTAT 2:e23820, 2013
44. Walford HH, Doherty TA: STAT6 and lung inflammation. JAKSTAT 2:e25301, 2013
45. Pylayeva-Gupta Y, Lee KE, Hajdu CH, et al: Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21:836-847, 2012
46. Ancrile B, Lim KH, Counter CM: Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 21:1714-1719, 2007
47. Corcoran RB, Contino G, Deshpande V, et al: STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res 71:5020-5029, 2011
48. Fukuda A, Wang SC, Morris JP 4th, et al: Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 19:441-455, 2011
49. Grivennikov S, Karin E, Terzic J, et al: IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-Associated cancer. Cancer Cell 15:103-113, 2009
50. Chang Q, Bournazou E, Sansone P, et al: The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia 15:848-862, 2013
51. Dauer DJ, Ferraro B, Song L, et al: Stat3 regulates genes common to both wound healing and cancer. Oncogene 24:3397-3408, 2005
52. Lai SY, Childs EE, Xi S, et al: Erythropoietinmediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene 24:4442-4449, 2005
53. Wormann SM, Diakopoulos KN, Lesina M, et al: The immune network in pancreatic cancer development and progression. Oncogene 33:2956-2967, 2014
54. Verstovsek S, Kantarjian H, Mesa RA, et al: Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363:1117-1127, 2010
55. Verstovsek S, Mesa RA, Gotlib J, et al: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799-807, 2012
56. Harrison C, Kiladjian JJ, Al-Ali HK, et al: JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366:787-798, 2012
57. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
58. National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. Bethesda, MD, US Department of Health and Human Services, 2010
59. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
60. Cella D: Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) scales, version 4. Chicago, IL, Center on Outcomes, Research, and Education (CORE), Northwestern University, 1997
61. McMillan DC, Crozier JE, Canna K, et al: Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 22:881-886, 2007
62. McMillan DC: An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc 67:257-262, 2008
63. Freelove R, Walling AD: Pancreatic cancer: Diagnosis and management. Am Fam Physician 73:485-492, 2006
64. Bonetto A, Aydogdu T, Jin X, et al: JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab 303:E410-421, 2012
65. Hanahan D, Weinberg RA: Hallmarks of cancer: The next generation. Cell 144:646-674, 2011
66. Proctor MJ, Morrison DS, Talwar D, et al: A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow inflammation outcome study. Eur J Cancer 47:2633-2641, 2011
67. Kermorgant S, Parker PJ: Receptor trafficking controls weak signal delivery: A strategy used by c-Met for STAT3 nuclear accumulation. J Cell Biol 182:855-863, 2008
68. Green MR, Rodig S, Juszczynski P, et al: Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: Implications for targeted therapy. Clin Cancer Res 18:1611-1618, 2012
69. Kortylewski M, Swiderski P, Herrmann A, et al: In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 27:925-932, 2009